Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a solution for intrauterine use. It provides a numbing effect for gynecologic procedures and is used in adult patients undergoing intrauterine interventions.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidbree (lidocaine) is employed in gynecologic procedures that require local anesthesia of the uterine cavity.

- Hysteroscopic surgery: provides analgesia to reduce patient discomfort during operative hysteroscopy. - IUD insertion: numbs the endocervical canal to facilitate smooth device placement. - Endometrial biopsy: minimizes pain associated with tissue sampling from the uterine lining.

Lidbree may cause a range of adverse reactions, most of which are mild and transient, while rare events can be serious.

Common Side Effects: - Burning sensation at application site - Mild uterine cramping - Nausea - Dizziness - Headache - Local irritation

Serious or Rare Side Effects: - Allergic reaction (rash, angioedema, anaphylaxis) - Cardiovascular toxicity (arrhythmia, hypotension) - Seizures - Methemoglobinemia - Severe hypotension - Respiratory depression

When using Lidbree, several safety measures should be observed to minimise risk.

- Allergy assessment: confirm no known hypersensitivity to lidocaine or amide‑type anesthetics. - Cardiac monitoring: observe heart rhythm and blood pressure during administration. - Dose limitation: use the lowest effective amount for the procedure. - Avoid intravascular injection: aspirate before injection to prevent systemic exposure. - Caution in hepatic impairment: reduce dose as lidocaine is metabolised by the liver. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lidbree can interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Amiodarone: may increase lidocaine plasma levels leading to toxicity. - Cimetidine: inhibits metabolism and raises systemic exposure. - Erythromycin: can reduce clearance and enhance adverse effects. - Class I antiarrhythmics (e.g., quinidine): additive cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate bradycardia. - Calcium channel blockers: can enhance cardiac depressant effects. - Other local anesthetics: risk of cumulative toxicity. - MAO inhibitors: may increase risk of hypertensive reactions.